These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 12181833)

  • 1. [Molecular cytogenetic monitoring of chimerism and minimal residual disease in patient with chronic myeloid leukemia after allogenic and syngenic bone marrow transplantation].
    Vinogradova OA; Savchenko VG; Domracheva EV; Liubimova LS; Ol'shanskaia IuV; Diachenko LV; Parovichnikova EN; Mendeleeva LP; Zakharova AV
    Ter Arkh; 2002; 74(7):38-44. PubMed ID: 12181833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study of the time course of mixed chimerism by fluorescent in situ hybridization in patients with chronic myeloid leukemia after allogenic transplantation of bone marrow].
    Vinogradova OA; Savchenko VG; Neverova AL; Diachenko LV; Domracheva EV; Liubimova LS; Mendeleeva LP
    Ter Arkh; 2001; 73(7):26-34. PubMed ID: 11523405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
    Elmaagacli AH; Runkel K; Steckel N; Opalka B; Trenschel R; Seeber S; Schaefer UW; Beelen DW
    Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Román J; Serrano J; Jiménez A; Castillejo JA; Reina ML; González MG; Rodríguez MC; García I; Sánchez J; Maldonado J; Torres A
    Haematologica; 2000 Feb; 85(2):173-80. PubMed ID: 10681725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of minimal residual disease and persistence of host-type hematopoiesis: a study in 28 patients after sex-mismatched, non-T cell-depleted allogeneic bone marrow transplantation for Philadelphia-chromosome positive chronic myelogenous leukemia.
    Elmaagacli AH; Becks HW; Beelen DW; Stockova J; Bützler R; Opalka B; Schaefer UW
    Bone Marrow Transplant; 1995 Dec; 16(6):823-9. PubMed ID: 8750276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Detection of minimal residual disease after allogeneic bone marrow transplantation in chronic myeloid leukemia].
    Liu Y; Fu J; Yu X; Chang Y; Xue W; Chen S; Lu D
    Zhonghua Xue Ye Xue Za Zhi; 1997 Mar; 18(3):140-2. PubMed ID: 15622775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
    Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential molecular monitoring of chimerism in chronic myeloid leukemia patients receiving donor lymphocyte transfusion for relapse after bone marrow transplantation.
    Rapanotti MC; Arcese W; Buffolino S; Iori AP; Mengarelli A; De Cuia MR; Cardillo A; Cimino G
    Bone Marrow Transplant; 1997 Apr; 19(7):703-7. PubMed ID: 9156248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effectiveness of allogeneic bone marrow transplantation in patients with acute leukemia in complete remission and in patients with chronic myeloid leukemia during the chronic phase].
    Liubimova LS; Savchenko VG; Mendeleeva LP; Kliasova GA; Gribanova EO; Demidova IA; Gal'tseva IV; Kuz'mina LA; Momotiuk KS; Kuliev RG
    Ter Arkh; 1999; 71(7):27-32. PubMed ID: 10481864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of remission state in chronic myeloid leukemia patients after bone marrow transplantation using cytogenetic and molecular genetic approaches.
    Arnold R; Bartram CR; Heinze B; Carbonell F; Wiesneth M; Hertenstein B; Schmeiser T; Heit W; Kubanek B; Heimpel H
    Bone Marrow Transplant; 1989 Jul; 4(4):389-92. PubMed ID: 2505880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorescent in situ hybridization on flow-sorted cells as a tool for evaluating minimal residual disease or chimerism after allogenic bone marrow transplantation.
    Cotteret S; Belloc F; Boiron JM; Bilhou-Nabera C; Dumain P; Boyer C; Lacombe F; Reiffers J; Bernard P
    Cytometry; 1998 Oct; 34(5):216-22. PubMed ID: 9822307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Is leukemic transformation of donor cells possible?].
    Vinogradova OA; Savchenko VG; Domracheva EV; Parovichnikova EN; Diachenko LV; Alimova GA; Mendeleeva LP; Liubimova LS; Sokolov AN; Zhelnova EI; Pokrovskaia OS
    Ter Arkh; 2004; 76(7):28-34. PubMed ID: 15379124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Allogenic bone marrow transplantation in chronic myeloid leukemias].
    Liubimova LS; Savchenko VG; Mendeleeva LP; Kuz'mina LA; Anukhina MV; Gribanova EO; Demidova IA; Misiurin AV; Vinogradova OA; Domracheva EV; Poreshina LP; Kut'ina RM; Shpakova AP; Matveenko AA; Kalinin NN; Gemdzhian EG
    Ter Arkh; 2004; 76(7):18-24. PubMed ID: 15379122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210(BCR-ABL) and p190(BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190(BCR-ABL) detection precede cytogenetic relapse.
    Serrano J; Roman J; Sanchez J; Jimenez A; Castillejo JA; Herrera C; Gonzalez MG; Reina L; Rodriguez MC; Alvarez MA; Maldonado J; Torres A
    Blood; 2000 Apr; 95(8):2659-65. PubMed ID: 10753848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FISH detection of mixed chimerism in 33 patients submitted to bone marrow transplantation.
    Palka G; Stuppia L; Di Bartolomeo P; Morizio E; Peila R; Franchi PG; Calabrese G
    Bone Marrow Transplant; 1996 Feb; 17(2):231-6. PubMed ID: 8640172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
    Kim YJ; Kim DW; Lee S; Min CK; Goh HG; Kim SH; Lee JY; Kim YL; Kim HJ; Kim HJ; Lee JW; Kim TG; Min WS; Kim CC
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):718-25. PubMed ID: 15389438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Successful treatment with donor leukocyte transfusion followed by interferon-alpha in a patient with relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation].
    Maeda A; Yamamoto K; Kotone Y; Yamashita K; Yoshinaga N; Hirata H; Asagoe K; Nohgawa M; Takahashi A; Ohno H; Tashima M; Sasada M
    Rinsho Ketsueki; 1998 Jun; 39(6):442-6. PubMed ID: 9695673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of detection of minimal residual disease by 'hypermetaphase' fluorescent in situ hybridization after allogeneic BMT for chronic myelogenous leukemia.
    Seong D; Giralt S; Fischer H; Hayes K; Glassman A; Arlinghaus R; Xu J; Kantarjian H; Siciliano M; Champlin R
    Bone Marrow Transplant; 1997 Mar; 19(6):565-70. PubMed ID: 9085736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.